Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO

Phase 3Trastuzumab BotidotinT-DM1Positive

AI Analysis

Summary

Sichuan Kelun-Biotech announced Phase III registrational study results of trastuzumab botidotin versus T-DM1 in HER2-positive breast cancer, published in the Journal of Clinical Oncology.

Clinical Trial Data

Phase

Phase III

Outcome Details

Phase III registrational study results published in JCO comparing trastuzumab botidotin versus T-DM1

Importance:7/10

Sentiment:

0.60

HER2-positive breast cancerantibody-drug conjugatePhase III resultsclinical trialoncology

Related Companies

$SKBBY

Read the original article

Published by PR Newswire Biotech on September 14, 2026 6:18 AM

Read Original